Search En menu ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 60,000,000
    Countries
    Sector(s)
    Denmark : € 60,000,000
    Industry : € 60,000,000
    Signature date(s)
    28/11/2016 : € 60,000,000

    Summary sheet

    Release date
    13 December 2016
    Status
    Reference
    Signed | 13/12/2016
    20160046
    Project name
    Promoter - financial intermediary
    ALK-ABELLO ANTI-ALLERGY TREATMENT RDI
    ALK-ABELLO A/S
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 60 million
    EUR 149 million
    Location
    Sector(s)
    Description
    Objectives

    Financing of ALK-Abello's market-leading research into allergic diseases. ALK is the world leader in allergy immunotherapy. The treatment is recognised by the World Health Organisation (WHO) as the only treatment that targets the cause of allergy and alters the natural course of the disease. The financing is expected to materially support the company's efforts in this domain.

    The project would consist of the promoter's research and development (R&D) activities from 2017 to 2019, related to research, development and life-cycle management of new, evidence-based immunotherapy drugs covering major respiratory allergies – house dust mite, grass pollen, tree pollen, ragweed pollen, and Japanese cedar pollen – further documenting the drug benefits in asthma treatment and asthma prevention, a disease associated with high unmet medical needs and market opportunities.

    Environmental aspects
    Procurement

    R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

    The promoter has been assessed by the EIB as being a private company not operating in the utilities sector and not having the status of a contracting entity, thus not subject to EU rules on public procurement. However, if after the project appraisal, the EIB were to conclude that the promoter is after all subject to EU public procurement legislation (i.e. Directive 2004/17/EC), then the Bank would require the promoter to ensure that contracts for the implementation of the project have been/will be tendered in accordance with the relevant applicable EU procurement legislation (Directive 2004/17/EC and Directive 92/13/EEC), with publication of tender notices in the Official Journal of the EU, as and where required.

    Comments

    /

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Documents

    Environmental and Social Data Sheet (ESDS) - ALK-ABELLO ANTI-ALLERGY TREATMENT RDI
    Publication Date
    16 Dec 2016
    Document language
    Main Topic
    Lending
    Document Number
    68878868
    Document Focus
    Environmental Information
    Project Number
    20160046
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now
    Environmental and Social Completion Sheet (ESCS) - ALK-ABELLO ANTI-ALLERGY TREATMENT RDI
    Publication Date
    30 Dec 2020
    Document language
    Main Topic
    Lending
    Document Number
    135773561
    Document Focus
    Environmental Information
    Project Number
    20160046
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications